GlassScriptPhysician profile
Abigail Souza
NPI 1003499013
$1,589.32
in general payments reported to CMS, 2019-2025
22 companies · $206 in 2025
The $206 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $169 · 2022: $470 · 2023: $424 · 2024: $320 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $950.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $949.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $497.61 | 2021-2023 | Breztri, Symbicort |
| Tg Therapeutics, INC. | $177.62 | 2023-2024 | |
| Janssen Scientific Affairs, LLC | $133.49 | 2025 | Tremfya |
| Electromed, INC. | $124.43 | 2021-2024 | Smartvest |
| Glaxosmithkline, LLC. | $113.24 | 2021-2025 | Trelegy Ellipta, Nucala |
| Bayer Healthcare Pharmaceuticals INC. | $109.12 | 2022 | |
| Octapharma USA, INC. | $46.30 | 2023-2024 | Octagam Immune Globulin (Human), Panzyga |
| Grifols USA, LLC | $35.89 | 2024 | Gamunex-C |
| Daiichi Sankyo INC. | $34.42 | 2024 | Injectafer |
| Eisai INC. | $33.71 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.35 | 2025 | Spevigo |
| Alnylam Pharmaceuticals INC. | $31.56 | 2023-2024 | Onpattro |
| Regeneron Healthcare Solutions, INC. | $27.66 | 2022 | |
| Genentech USA, INC. | $24.77 | 2024 | Ocrevus |
| Merck Sharp & Dohme LLC | $24.68 | 2024 | Zerbaxa |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $23.51 | 2024 | Ultomiris |
| Sandoz INC. | $23.08 | 2023 | |
| Baxter Healthcare | $22.48 | 2022 | |
| Sanofi-Aventis U.S. LLC | $19.94 | 2024 | |
| Abbvie INC. | $19.88 | 2023 | |
| Tersera Therapeutics LLC | $17.83 | 2025 | Quzyttir |
| Takeda Pharmaceuticals U.S.A., INC. | $14.75 | 2023 | Vpriv |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail Souza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.